PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy

Adrian Lowe, John Su, Mimi Tang, Caroline J Lodge, Melanie Matheson, Katrina J Allen, George Varigos, Arun Sasi, Noel Cranswick, Simone Hamilton, Colin F Robertson, Jennie Hui, Michael Abramson, Shaie O'Brien, Shyamali Dharmage, Adrian Lowe, John Su, Mimi Tang, Caroline J Lodge, Melanie Matheson, Katrina J Allen, George Varigos, Arun Sasi, Noel Cranswick, Simone Hamilton, Colin F Robertson, Jennie Hui, Michael Abramson, Shaie O'Brien, Shyamali Dharmage

Abstract

Introduction: The skin is an important barrier against environmental allergens, but infants have relatively impaired skin barrier function. There is evidence that impaired skin barrier function increases the risk of allergic sensitisation, atopic dermatitis (AD) and food allergy. We hypothesise that regular prophylactic use of emollients, particularly those that are designed to improve skin barrier structure and function, will help prevent these conditions. With the aim of determining if application of a ceramide-dominant emollient two times per day reduces the risk of AD and food allergy, we have commenced a multicentre phase III, outcome assessor blinded, randomised controlled trial of this emollient applied from birth to 6 months.

Methods and analysis: Infants (n=760) with a family history of allergic disease will be recruited from maternity hospitals in Melbourne. The primary outcomes are as follows: the presence of AD, assessed using the UK Working Party criteria, and food allergy using food challenge, in the first 12 months of life as assessed by a blinded study outcome assessor. Secondary outcomes are as follows: food sensitisation (skin prick test), skin barrier function, AD severity, the presence of new onset AD after treatment cessation (between 6 and 12 months) and the presence of parent reported AD/eczema. Recruitment commenced in March 2018.

Ethics and dissemination: The PEBBLES Study is approved by the Human Research Ethics Committees of the Royal Children's Hospital (RCH) (#37090A) and the Mercy Hospital for Women (2018-008). Parents or guardians will provide written informed consent. Outcomes will be disseminated through peer-reviewed publications and presented at scientific conferences.

Trial registration numbers: ACTRN12617001380381 and NCT03667651.

Keywords: allergy; asthma; eczema; paediatric dermatology.

Conflict of interest statement

Competing interests: MT is a member of the Medical Advisory Board (Oceania) for Nestle Nutrition Institute, a member of the Medical Advisory Board (Australia New Zealand) for Danone Nutricia and a member of the Scientific Advisory Board for Immunology Allergy (Global) for Danone Nutricia; and has received lecture fees from Danone and Nestle Nutrition Institute; and has received travel fees from APAPARI. KJA has received speaker’s honoraria from Abbott, Danone, Nestle and Alphapharm. MA has received investigator-initiated grants from Pfizer and Boehringer-Ingelheim for unrelated research. He has also received from Sanofi assistance with conference attendance and an honorarium for an unrelated consultancy.

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Study flow diagram.

References

    1. Ierodiakonou D, Garcia-Larsen V, Logan A, et al. . Timing of allergenic food introduction to the infant diet and risk of allergic or autoimmune disease: a systematic review and meta-analysis. JAMA 2016;316:1181–92. 10.1001/jama.2016.12623
    1. Martin PE, Eckert JK, Koplin JJ, et al. . Which infants with eczema are at risk of food allergy? Results from a population-based cohort. Clin Exp Allergy 2015;45:255–64. 10.1111/cea.12406
    1. Lowe AJ, Carlin JB, Bennett CM, et al. . Do boys do the atopic march while girls dawdle? J Allergy Clin Immunol 2008;121:1190–5. 10.1016/j.jaci.2008.01.034
    1. Lowe AJ, Abramson MJ, Hosking CS, et al. . The temporal sequence of allergic sensitization and onset of infantile eczema. Clin Exp Allergy 2007;37:536–42. 10.1111/j.1365-2222.2007.02691.x
    1. Hopper JL, Bui QM, Erbas B, et al. . Does eczema in infancy cause hay fever, asthma, or both in childhood? Insights from a novel regression model of sibling data. J Allergy Clin Immunol 2012;130:1117–22. 10.1016/j.jaci.2012.08.003
    1. Martin PE, Matheson MC, Gurrin L, et al. . Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades. J Allergy Clin Immunol 2011;127:1473–9. 10.1016/j.jaci.2011.02.041
    1. Burgess JA, Dharmage SC, Byrnes GB, et al. . Childhood eczema and asthma incidence and persistence: a cohort study from childhood to middle age. J Allergy Clin Immunol 2008;122:280–5. 10.1016/j.jaci.2008.05.018
    1. Khan SJ, Dharmage SC, Matheson MC, et al. . Is the atopic march related to confounding by genetics and early-life environment? A systematic review of sibship and twin data. Allergy 2018;73:17–28. 10.1111/all.13228
    1. Dharmage SC, Lowe AJ, Matheson MC, et al. . Atopic dermatitis and the atopic march revisited. Allergy 2014;69:17–27. 10.1111/all.12268
    1. Nikolovski J, Stamatas GN, Kollias N, et al. . Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol 2008;128:1728–36. 10.1038/sj.jid.5701239
    1. Choi MJ, Maibach HI. Role of ceramides in barrier function of healthy and diseased skin. Am J Clin Dermatol 2005;6:215–23. 10.2165/00128071-200506040-00002
    1. Kelleher M, Dunn-Galvin A, Hourihane JO, et al. . Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year. J Allergy Clin Immunol 2015;135:930–5. 10.1016/j.jaci.2014.12.013
    1. Lowe AJ, Su JC, Allen KJ, et al. . A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: the PEBBLES pilot study. Br J Dermatol 2018;178:e19–21. 10.1111/bjd.15747
    1. Simpson EL, Chalmers JR, Hanifin JM, et al. . Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol 2014;134:818–23. 10.1016/j.jaci.2014.08.005
    1. Horimukai K, Morita K, Narita M, et al. . Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol 2014;134:824–30. 10.1016/j.jaci.2014.07.060
    1. Lowe AJ, Leung DYM, Tang MLK, et al. . The skin as a target for prevention of the atopic march. Ann Allergy Asthma Immunol 2018;120:145–51. 10.1016/j.anai.2017.11.023
    1. Hoeger PH, Schreiner V, Klaassen IA, et al. . Epidermal barrier lipids in human vernix caseosa: corresponding ceramide pattern in vernix and fetal skin. Br J Dermatol 2002;146:194–201. 10.1046/j.1365-2133.2002.04584.x
    1. Man MQ M, Feingold KR, Thornfeldt CR, et al. . Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996;106:1096–101. 10.1111/1523-1747.ep12340135
    1. Hachem JP, Crumrine D, Fluhr J, et al. . pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol 2003;121:345–53. 10.1046/j.1523-1747.2003.12365.x
    1. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009;8:1106–11.
    1. Hengge UR, Ruzicka T, Schwartz RA, et al. . Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1–15. Quiz 6-8 10.1016/j.jaad.2005.01.010
    1. Lowe AJ, Tang ML, Dharmage SC, et al. . A phase I study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates. BMC Dermatol 2012;12:3 10.1186/1471-5945-12-3
    1. Williams HC, Burney PG, Pembroke AC, et al. . The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994;131:406–16. 10.1111/j.1365-2133.1994.tb08532.x
    1. Koplin JJ, Tang ML, Martin PE, et al. . Predetermined challenge eligibility and cessation criteria for oral food challenges in the HealthNuts population-based study of infants. J Allergy Clin Immunol 2012;129:1145–7. 10.1016/j.jaci.2011.09.044
    1. Hanifin JM, Thurston M, Omoto M, et al. . The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001;10:11–18. 10.1034/j.1600-0625.2001.100102.x
    1. Simpson EL, Keck LE, Chalmers JR, et al. . How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies. J Allergy Clin Immunol 2012;130:137–44. 10.1016/j.jaci.2012.01.075
    1. Asher MI, Keil U, Anderson HR, et al. . International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. Eur Respir J 1995;8:483–91. 10.1183/09031936.95.08030483
    1. Barbier N, Paul C, Luger T, et al. . Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004;150:96–102. 10.1111/j.1365-2133.2004.05696.x
    1. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009;339:b2433 10.1136/bmj.b2433
    1. Kim J, Kim BE, Lee J, et al. . Epidermal thymic stromal lymphopoietin predicts the development of atopic dermatitis during infancy. J Allergy Clin Immunol 2016;137:1282–5. 10.1016/j.jaci.2015.12.1306
    1. Chng KR, Tay AS, Li C, et al. . Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat Microbiol 2016;1:16106 10.1038/nmicrobiol.2016.106
    1. Glatz M, Jo JH, Kennedy EA, et al. . Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis. PLoS One 2018;13:e0192443 10.1371/journal.pone.0192443
    1. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. . Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–6. 10.1038/ng1767
    1. Pawankar R, Canonica GW, Holgate ST, et al. . The WAO White Book on Allergy. 2013.
    1. Asher MI, Montefort S, Björkstén B, et al. . Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368:733–43. 10.1016/S0140-6736(06)69283-0
    1. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010:CD001186 10.1002/14651858.CD001186.pub2
    1. Tang ML, Ponsonby AL, Orsini F, et al. . Administration of a probiotic with peanut oral immunotherapy: a randomized trial. J Allergy Clin Immunol 2015;135:737–44. 10.1016/j.jaci.2014.11.034
    1. Foisy M, Boyle RJ, Chalmers JR, et al. . Overview of reviews the prevention of eczema in infants and children: an overview of cochrane and non-cochrane reviews. Evid Based Child Health 2011;6:1322–39. 10.1002/ebch.827
    1. Lodge CJ, Allen KJ, Lowe AJ, et al. . Overview of evidence in prevention and aetiology of food allergy: a review of systematic reviews. Int J Environ Res Public Health 2013;10:5781–806. 10.3390/ijerph10115781
    1. Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. . Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006;38:337–42. 10.1038/ng1743
    1. Chen H, Common JE, Haines RL, et al. . Wide spectrum of filaggrin-null mutations in atopic dermatitis highlights differences between Singaporean Chinese and European populations. Br J Dermatol 2011;165:106–14. 10.1111/j.1365-2133.2011.10331.x
    1. Flohr C, England K, Radulovic S, et al. . Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol 2010;163:1333–6. 10.1111/j.1365-2133.2010.10068.x
    1. Tan HT, Ellis JA, Koplin JJ, et al. . Filaggrin loss-of-function mutations do not predict food allergy over and above the risk of food sensitization among infants. J Allergy Clin Immunol 2012;130:1211–3. 10.1016/j.jaci.2012.07.022
    1. Ashley SE, Tan HT, Vuillermin P, et al. . The skin barrier function gene SPINK5 is associated with challenge-proven IgE-mediated food allergy in infants. Allergy 2017;72:1356–64. 10.1111/all.13143
    1. Silverberg JI, Thyssen JP, Paller AS, et al. . What’s in a name? Atopic dermatitis or atopic eczema, but not eczema alone. Allergy 2017;72:2026–30. 10.1111/all.13225
    1. Lowe AJ, Hosking CS, Bennett CM, et al. . Skin prick test can identify eczematous infants at risk of asthma and allergic rhinitis. Clin Exp Allergy 2007;37:1624–31. 10.1111/j.1365-2222.2007.02822.x
    1. Kusel MM, Holt PG, de Klerk N, et al. . Support for 2 variants of eczema. J Allergy Clin Immunol 2005;116:1067–72. 10.1016/j.jaci.2005.06.038
    1. Martin PE, Koplin JJ, Eckert JK, et al. . The prevalence and socio-demographic risk factors of clinical eczema in infancy: a population-based observational study. Clin Exp Allergy 2013;43:642–51. 10.1111/cea.12092
    1. Osborne NJ, Koplin JJ, Martin PE, et al. . Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. J Allergy Clin Immunol 2011;127:668–76. 10.1016/j.jaci.2011.01.039
    1. Koplin JJ, Allen KJ, Gurrin LC, et al. . The impact of family history of allergy on risk of food allergy: a population-based study of infants. Int J Environ Res Public Health 2013;10:5364–77. 10.3390/ijerph10115364

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera